Last reviewed · How we verify
NCT03826888
Measurement of Different Anti-Müllerian Hormone Isoforms in Expected Poor Responders
trial in Anti-Mullerian Hormone Isoforms in 72 participants. Completed in 30 May 2022.
23 December 2021
Quick facts
| Lead sponsor | ART Fertility Clinics LLC |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 72 |
| Start date | 25 February 2019 |
| Primary completion | 23 December 2021 |
| Estimated completion | 30 May 2022 |
| Sites | 1 location across United Arab Emirates |
Conditions studied
- Anti-Mullerian Hormone Isoforms — all drugs for Anti-Mullerian Hormone Isoforms →
Sponsor
ART Fertility Clinics LLC
Who can join
Eligibility, female only, with Anti-Mullerian Hormone Isoforms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study wants to evaluate significant clinical impact of different AMH isoforms in serum can be present or absent in expected poor responder participants. The specific AMH isoforms could therefore be measured in expected poor responder participants in order to obtain a more realistic clinical picture and therefore be able to give proper information to the participants and selection of medication dose for ovarian stimulation.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
The role of bioavailable inhibin B in predicting oocyte yield in expected poor responders: the forgotten marker?
Melado L, Kumar A, Kalra B, Kalafat E, et al · · 2025 · cited 1× · PMID 40866738 · DOI 10.1007/s10815-025-03637-9 -
How to enhance prediction of clinical outcomes in poor responders: integrating high-specific assays for anti-mullerian hormone with antral follicle count.
Melado L, Kumar A, Kalra B, Kalafat E, et al · · 2025 · PMID 41089290 · DOI 10.3389/fendo.2025.1654365
Verify or expand the search:
- PubMed search for NCT03826888
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other ART Fertility Clinics LLC trials
Trials by the same sponsor.
- NCT07270250 — Impact of Dry vs Humidified Culture Conditions on Blastocyst Development and Aneuploidy: A Time-lapse Sibling Oocyte Stu · NA · not yet recruiting
- NCT06879002 — Comparing IVF/ICSI Cycle Outcomes of Post Ovulation Ovarian Stimulation Protocol With Elonva Without GnRH Antagonist to · not yet recruiting
- NCT07093619 — Evaluating the Utility of Implementing Microfluids for Sperm Preparation Compared to Conventional Method of Density Grad · NA · recruiting
- NCT06732843 — Does Recombinant FSH (rFSH, i.g. Gonal F®) as Compared to Human Menopausal Gonadotrophin (hMG) Affect Telomere Length of · recruiting
- NCT07014267 — Virtual Reality for Mindfulness and Anxiety Reduction in Fertility Procedures · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03826888 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by ART Fertility Clinics LLC
- Last refreshed: 8 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03826888.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing